The clinical differentiation between the two approved oral agents matters directly to payers, health technology assessment bodies, and commercial teams. Oral semaglutide requires fasting administration and timing restrictions to secure adequate absorption, a consequence of its peptide-based chemistry. Orforglipron, as a small-molecule agent, carries no such restrictions and can be taken at any time of day without food or fluid requirements. Data from Novo Nordisk’s OASIS 4 Phase III trial showed that oral semaglutide produced a clinically meaningful mean reduction in body weight after 64 weeks in patients with obesity or overweight. Lilly's ATTAIN Phase III programme showed orforglipron delivering clinically meaningful weight loss across a broad and diverse trial population. European payers, who have not yet seen formal health technology assessment submissions for these molecules, will scrutinise the clinical comparators selected, which increasingly include quality-of-weight-loss and lean-mass-preservation endpoints rather than headline percentage reduction alone, as well as the cost structures underpinning manufacturer proposals.
Reimbursement Frameworks Designed for Injectables Now Face Revision
European national reimbursement frameworks were, by and large, shaped around the injectable GLP-1 portfolio as it existed before 2025. France became the first European Union member state to formally reimburse GLP-1 receptor agonists for obesity when the Health Ministry confirmed, through two ministerial decrees published in the French Journal Officiel on 28 May 2026, that semaglutide (Wegovy) and tirzepatide (Mounjaro) would be reimbursed from 15 June 2026 at a nationally administered price, for adults meeting specific clinical and comorbidity thresholds. This decision, building on favourable assessments issued by the Haute Autorité de Santé for both molecules in late 2024 and 2025, respectively, marks the most far-reaching structural access decision for anti-obesity medicines in Europe to date. Germany's Gemeinsamer Bundesausschuss has maintained its exclusion of GLP-1 therapies from statutory health insurance coverage for the obesity indication, citing a legal resolution dating back to 2004. In the United Kingdom, NICE has issued technology appraisal guidance recommending both semaglutide and tirzepatide for weight management in specialist settings. To manage capacity constraints, NHS England introduced a phased rollout of tirzepatide by integrating its prescribing into GP Quality and Outcomes Framework (QOF) indicators starting in April 2026. The arrival of oral agents introduces a question that injectable reimbursement architectures did not need to answer: whether ease of administration, by lowering the tolerability barrier that limits adherence and widening the pool of patients who actually stay on treatment, changes the value case put to payers. National health technology assessment agencies, including the National Institute for Health and Care Excellence and the Haute Autorité de Santé, will need to consider not only clinical weight loss outcomes but also comparisons between the oral and injectable routes, patient-reported outcomes relating to convenience, and cost-per-outcome modelling for populations that differ from those enrolled in injectable trials. Pharmaceutical manufacturers will enter this process recognising that precedents established in the injectable market may not automatically apply. Obesity Therapies Europe 2027 examines how commercial, market access, and health economics and outcomes research teams are building the evidence packages and pricing proposals that will define this next reimbursement cycle.
